Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.

导出 OA

翻译打印收藏纠错

作者： Alexander,Quaas ^[1] ; Carina,Heydt ^[2] ; Dirk,Waldschmidt ^[3] ; Hakan,Alakus ^[4] ; Thomas,Zander ^[5] ; Tobias,Goeser ^[3] ; Philipp,Kasper ^[3] ; Christiane,Bruns ^[4] ; Anna,Brunn ^[6] ; Wilfried,Roth ^[7] ; Nils,Hartmann ^[7] ; Anne,Bunck ^[8] ; Matthias,Schmidt ^[9] ; Reinhard,Buettner ^[2] ; Sabine,Merkelbach-Bruse ^[2]

作者单位： Institute of Pathology, University of Cologne, Cologne, Germany. alexander.quaas@uk-koeln.de. ^[1] Institute of Pathology, University of Cologne, Cologne, Germany. ^[2] Department of Hepato- and Gastroenterology, University of Cologne, Cologne, Germany. ^[3] Department of Visceral Surgery, University of Cologne, Cologne, Germany. ^[4] Department of Oncology and Hematology, University of Cologne, Cologne, Germany. ^[5] Institute of Neuropathology, University of Cologne, Cologne, Germany. ^[6] Institute of Pathology, University of Mainz, Mainz, Germany. ^[7] Department of Radiology, University of Cologne, Cologne, Germany. ^[8] Department of Nuclear Medicine, University of Cologne, Cologne, Germany. ^[9]

关键词 BRCA mutation ERBB2 mutation Microsatellite-instability PARP-inhibition Small bowel adenocarcinoma